At a glance
- Originator Eli Lilly and Company
- Class Anti-ischaemics; Antineoplastics; Naphthalenes; Pyrans
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 06 Aug 1998 No-Development-Reported for Ischaemic heart disorders in USA (Unknown route)
- 24 Oct 1996 New profile
- 24 Oct 1996 Preclinical development for Ischaemic heart disorders in USA (Unknown route)